Responses
Regular Abstracts – Part 2
Biomarkers, Immune Monitoring and Novel Technologies
222-G Beyond PD-L1: unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
Compose a Response to This Article
Other responses
No responses have been published for this article.
